Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 18/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369218 | 0.94 | PPARD (0.69) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL5711594 | 0.85 | MAOB (0.74) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL7645821 | 0.85 | MAOB (0.71) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL30231667 | 0.85 | MAOB (0.71) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL3210641 | 0.84 | MAOB (0.65) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL9043942 | 0.83 | MAOB (0.70) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL429049 | 0.81 | MAOB (0.67) | MAOBPPARDMAOAALDH1A1CYP3A4 | |
| SCHEMBL5711605 | 0.81 | MAOB (0.73) | MAOBPPARD | |
| SCHEMBL21064541 | 0.81 | MAOB (0.73) | MAOBPPARD | |
| SCHEMBL21052036 | 0.81 | PPARD (0.74) | MAOBPPARDMAOAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1751127-A2 | NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113529-A2 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | MAOB 838/4885PPARD 1639/4885MAOA 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.